Last Price$33.90.6%
Market Cap$15.2B
LTM Gross Profit
$1,672.7M
YoY Growth
+1.9%
3Y CAGR
-5.9%
5Y CAGR
+20.8%
Stock quality & Intrinsic value
6/10
430.9% undervalued
Royalty Pharma plc Gross Profit
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $1,652.4M | $1,877.4M | $1,564.7M | $1,658.9M | $794.9M | $2,033.9M | $2,266.5M | $2,231.5M | $1,793.9M | $2,264.0M |
Overvalued or undervalued?
Check the intrinsic value for RPRX
and see if it's the right time to invest.
Royalty Pharma plc (RPRX) Gross Profit comparison analysis
General
LTM Gross Profit
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Royalty Pharma plcRPRX
$1,672.7M
1.9%
(5.9%)
20.8%
Median Peer Set
$2,767.9M
18.9%
11.9%
14.0%
Novo Nordisk A/SNVO
$35.6B
25.0%
28.0%
19.3%
Regeneron Pharmaceuticals, Inc.REGN
$12.3B
6.8%
(3.3%)
11.7%
Vertex Pharmaceuticals IncorporatedVRTX
$9,475.3M
10.1%
12.4%
21.3%
Incyte CorporationINCY
$3,912.7M
13.7%
11.3%
13.9%
BioNTech SEBNTX
$2,781.1M
(39.4%)
(37.9%)
N/A
BeiGene, Ltd.BGNE
$2,754.8M
178.8%
N/A
N/A
United Therapeutics CorporationUTHR
$2,567.7M
24.0%
18.0%
14.0%
argenx SEARGX
$1,961.3M
117.3%
65.2%
101.8%
Alnylam Pharmaceuticals, Inc.ALNY
$1,924.9M
26.8%
39.8%
58.1%
Summit Therapeutics Inc.SMMT
($67.0K)
(96.7%)
N/A
N/A
RPRX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,652.4 0.0% | 1,877.4 13.6% | 1,597.9 (14.9%) | 1,794.9 12.3% | 1,814.3 1.1% | 2,122.0 17.0% | 2,289.5 7.9% | 2,237.2 (2.3%) | 2,354.6 5.2% | 2,264.0 (3.8%) |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 33.3 | 136.0 | 1,019.3 | 88.1 | 23.0 | 5.7 | 560.7 | 0.0 |
% margin | 1,652.4 100.0% | 1,877.4 100.0% | 1,564.7 97.9% | 1,658.9 92.4% | 794.9 43.8% | 2,033.9 95.8% | 2,266.5 99.0% | 2,231.5 99.7% | 1,793.9 76.2% | 2,264.0 100.0% |
| Operating Expenses | 790.0 | 1,086.3 | 658.2 | 430.4 | (808.9) | 527.0 | 858.7 | 1,314.3 | 862.4 | 971.0 |
| Research & Development Expenses (R&D) | 98.4 | 91.0 | 117.9 | 392.6 | 83.0 | 26.0 | 200.1 | 177.1 | 52.0 | 2.0 |
| Selling, General & Administrative Expenses (SG&A) | 121.4 | 69.5 | 106.4 | 61.9 | 103.4 | 182.0 | 182.8 | 227.3 | 249.7 | 237.0 |
% margin | 794.3 48.1% | 722.9 38.5% | 939.7 58.8% | 1,364.4 76.0% | 2,623.2 144.6% | 1,595.0 75.2% | 1,430.7 62.5% | 977.5 43.7% | 1,492.2 63.4% | 1,292.0 57.1% |
| Interest Income | 0.0 | 0.0 | 6.8 | 24.4 | 22.3 | 28.4 | 53.5 | 78.3 | 72.3 | 0.0 |
| Interest Expense | 224.4 | 238.9 | 247.3 | 280.0 | 268.6 | 157.0 | 166.1 | 188.0 | 187.2 | 226.0 |
| Pre-tax Income | 758.7 | 761.9 | 1,343.2 | 1,517.9 | 2,461.4 | 1,702.0 | 1,241.2 | 230.1 | 1,700.1 | 1,331.0 |
% effective tax rate | 177.3 23.4% | 196.0 25.7% | 542.7 40.4% | 433.4 28.6% | 349.3 14.2% | 1,147.0 67.4% | 762.4 61.4% | 187.2 81.4% | 0.0 0.0% | 472.0 35.5% |
% margin | 581.4 35.2% | 565.9 30.1% | 1,210.0 75.7% | 1,377.7 76.8% | 2,348.5 129.4% | 495.2 23.3% | 478.8 20.9% | 42.8 1.9% | 1,134.8 48.2% | 859.0 37.9% |
| EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 3.41 | 1.92 |
| Diluted EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 2.53 | 1.45 |
% margin | 862.4 52.2% | 1,069.0 56.9% | 973.0 60.9% | 1,397.7 77.9% | 2,647.1 145.9% | 1,683.5 79.3% | 1,453.7 63.5% | 928.6 41.5% | 1,887.3 80.2% | 1,292.0 57.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Royalty Pharma plc's Gross Profit?
As of today, Royalty Pharma plc's last 12-month Gross Profit is $1,672.7M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Royalty Pharma plc's Gross Profit growth rate?
Over the last year, Royalty Pharma plc's Gross Profit growth was 1.9%. The average annual Gross Profit growth rates for Royalty Pharma plc have been (7.2%) over the past three years, 20.8% over the past five years.